StreetInsider.com News Articles

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 26 Oct 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 93,320 common shares of the Company (the "Options") with effective grant dates of October 26, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 26 Oct 2026 16:01:00 -0400

RBC Capital on Definium Therapeutics Inc (DFTX): 'Broader Pullback Creates Compelling Entry Point'

Mon, 19 Oct 2026 09:30:22 -0400

RBC Capital analyst Brian Ambrahams reiterated an Outperform rating and $66.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).

The analyst commented: "Broader Pullback Creates Compelling Entry Point In Transformative, DeRisked Name; Shares of DFTX are down ~30% from recent highs, despite a series of '120 ph.III data across GAD and MDD that we believe represents some of the strongest efficacy data ever across these indications and is very likely to support approval next year. We acknowledge that commercial scalability remains a primary investor concern that may not be immediately addressable before launch, though our prior survey of Spravato centers and

Definium Therapeutics Announces New Employee Inducement Grants

Tue, 13 Oct 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 45,940 common shares of the Company (the "Options") with effective grant dates of October 13, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period

Definium Therapeutics Announces New Employee Inducement Grants

Tue, 13 Oct 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 45,940 common shares of the Company (the "Options") with effective grant dates of October 13, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period

JPMorgan Starts Definium Therapeutics Inc (DFTX) at Overweight

Fri, 09 Oct 2026 05:11:34 -0400

JPMorgan initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Overweight rating and a price target of $84.00.

For an analyst ratings summary and ratings history on Definium Therapeutics Inc click here. For more ratings news on Definium Therapeutics Inc click here.

Shares of Definium Therapeutics Inc closed at $34.18 yesterday.

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Wed, 30 Sep 2026 15:35:07 -0400

Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.

1. Delphia Therapeutics (DFTX)

The company's single-dose oral psychedelic DT120 has produced three positive Phase III datasets in major depressive disorder and generalized anxiety disorder, each addressing over 20 million U.S. patients. A pre-NDA meeting in Q4 2026 should support an NDA submission in

Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Wed, 30 Sep 2026 15:35:07 -0400

1. Delphia Therapeutics (DFTX)

Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Wed, 30 Sep 2026 15:35:07 -0400

1. Delphia Therapeutics (DFTX)

Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Wed, 30 Sep 2026 15:35:07 -0400

1. Delphia Therapeutics (DFTX)

Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Wed, 30 Sep 2026 15:35:07 -0400

1. Delphia Therapeutics (DFTX)

Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Wed, 30 Sep 2026 15:35:07 -0400

1. Delphia Therapeutics (DFTX)

Form 4 Definium Therapeutics, For: Sep 25 Filed by: Karlin Daniel

Tue, 29 Sep 2026 21:16:00 -0400

si-local-file:///var/storage/secattach/20260929/27123837.html

Form 4 Definium Therapeutics, For: Sep 25 Filed by: Barrow Robert

Tue, 29 Sep 2026 21:14:00 -0400

si-local-file:///var/storage/secattach/20260929/27123836.html

Form 4 Definium Therapeutics, For: Sep 25 Filed by: Wiley Matthew T.

Tue, 29 Sep 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260929/27123834.html

Form 4 Definium Therapeutics, For: Sep 25 Filed by: Sullivan Mark

Tue, 29 Sep 2026 21:11:00 -0400

si-local-file:///var/storage/secattach/20260929/27123833.html

Form 4 Definium Therapeutics, For: Sep 25 Filed by: Roberts Brandi

Tue, 29 Sep 2026 21:09:00 -0400

si-local-file:///var/storage/secattach/20260929/27123831.html

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 28 Sep 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of September 28, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 28 Sep 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of September 28, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with